02496.HK
Wuhan YZY Biopharma Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.30
−8.33%Year over year
Reported trailing growth
- Revenue
- -21.4%
- EBITDA
- +3.0%
- EBIT
- +7.0%
- EPS
- +4.3%
- Free cash flow
- +59.7%
- Operating cash flow
- +60.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +206.5%
- EBITDA
- +3.8%
- EBIT
- +10.3%
- Net income
- +15.4%
- EPS
- +16.0%
- Free cash flow
- +78.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025